Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DDN001
MIFTS: 52

Duodenal Ulcer

Categories: Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Duodenal Ulcer

About this section

MalaCards integrated aliases for Duodenal Ulcer:

Name: Duodenal Ulcer 12 54 43 15 17 71 32
Stress Ulcer 12 54 71
Curling Ulcer 12 71
Stress Ulcer of Stomach 71
Duodenal Ulcer Disease 54
Curling's Ulcers 12
Duodenal Ulcers 15

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1724
ICD9CM 34 532
MeSH 43 D004381
NCIt 49 C26755
SNOMED-CT 67 39755000 51868009
ICD10 32 K26
UMLS 71 C0010474 C0013295 C0400807 more
Sources

Summaries for Duodenal Ulcer

About this section
MalaCards based summary : Duodenal Ulcer, also known as stress ulcer, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and duodenitis. An important gene associated with Duodenal Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ondansetron and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are digestive/alimentary and immune system

Sources

Related Diseases for Duodenal Ulcer

About this section

Diseases in the Duodenal Ulcer family:

Duodenal Ulcer Due to Antral G-Cell Hyperfunction

Diseases related to Duodenal Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 907)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 33.0 S100A8 HRH2 GAST EGF
2 duodenitis 31.6 TNF S100A8 INS GAST
3 helicobacter pylori infection 31.5 S100A8 IL1B GAST CYP2C19 CXCL8 CXCL1
4 peptic ulcer perforation 31.4 S100A8 HRH2 GAST
5 gastroduodenitis 31.2 S100A8 GAST
6 hernia, hiatus 31.2 HRH2 GAST CYP2C19
7 active peptic ulcer disease 31.1 SST HRH2 CYP2C19
8 peritonitis 31.1 TNF IL6 IL1B IL10 CXCL8
9 cholelithiasis 31.1 SST INS GAST CCK
10 duodenogastric reflux 31.0 SST SCT GAST CCK
11 cholecystitis 31.0 S100A8 EGF CCK
12 dumping syndrome 31.0 SST SCT INS GAST CCK
13 obstructive jaundice 30.9 TNF IL6 GRP CXCL8
14 peptic ulcer disease 30.9 TNF SST SCT S100A8 INS IL1RN
15 opisthorchiasis 30.9 TNF IL1B CXCL8
16 intestinal obstruction 30.9 TNF SST IL6
17 pulmonary tuberculosis 30.8 TNF IL6 IL1B IL10
18 portal hypertension 30.8 TNF SST INS CXCL8
19 arteriovenous malformation 30.7 TNF IL6 IL1B
20 zollinger-ellison syndrome 30.7 SST SCT HRH2 GRP GAST EGF
21 pernicious anemia 30.6 SST SCT GAST
22 amebiasis 30.6 TNF IL1B CXCL8
23 postgastrectomy syndrome 30.5 SST INS GAST
24 purpura 30.5 TNF IL6 IL10
25 cytomegalovirus infection 30.5 TNF IL6 IL1B CXCL8
26 varicose veins 30.5 TNF IL6 CXCL8
27 gastrinoma 30.4 SST SCT INS GRP GAST
28 bile reflux 30.4 SCT S100A8 GAST CCK
29 pustulosis of palm and sole 30.4 TNF IL1RN CXCL8
30 leptin deficiency or dysfunction 30.4 TNF INS IL6 CCK
31 appendicitis 30.3 TNF S100A8 IL6 IL1B IL10 CXCL8
32 gastric neuroendocrine neoplasm 30.3 SST GAST
33 sarcoidosis 1 30.3 TNF LTA IL1RN IL1B
34 lymphadenitis 30.3 TNF IL1B IL10 CXCL8
35 haemophilus influenzae 30.3 TNF CXCL8
36 gastroparesis 30.3 SST GAST CCK
37 allergic hypersensitivity disease 30.3 TNF IL10 HRH2 CXCL8
38 cholangitis 30.3 TNF SST IL6 IL10 CXCL8
39 somatostatinoma 30.2 SST INS GAST
40 biliary dyskinesia 30.2 SST SCT CCK
41 graft-versus-host disease 30.2 TNF IL6 IL1B IL10
42 gallbladder disease 30.2 SST INS IL10 CCK
43 colitis 30.2 TNF IL6 IL1B IL10 CXCL8
44 bronchopneumonia 30.2 TNF IL6 IL1B IL10 CXCL8
45 status asthmaticus 30.2 IL1RN IL10 CXCL8
46 exanthem 30.2 TNF IL6 IL1RN IL1B IL10 CXCL8
47 urticaria 30.2 TNF IL6 IL10 HRH2
48 constipation 30.2 TNF SST INS IL6 GRP GAST
49 esophagitis 30.1 TNF IL6 IL1B IL10 HRH2 GAST
50 insulinoma 30.1 SST SCT INS GAST

Graphical network of the top 20 diseases related to Duodenal Ulcer:



Diseases related to Duodenal Ulcer
Sources

Symptoms & Phenotypes for Duodenal Ulcer

About this section

MGI Mouse Phenotypes related to Duodenal Ulcer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 EGF GAST HRH2 IL10 IL6 INS
2 immune system MP:0005387 9.36 EGF GAST IL10 IL1B IL1RN IL6
Sources

Drugs & Therapeutics for Duodenal Ulcer

About this section

Drugs for Duodenal Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ondansetron Approved Phase 4 99614-02-5 4595
2
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Sucralfate Approved Phase 4 54182-58-0
7
Ethanol Approved Phase 4 64-17-5 702
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
10
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
11
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
12
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
19
Azithromycin Approved Phase 4 83905-01-5 447043 55185
20
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
21
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
22
Famotidine Approved Phase 4 76824-35-6 3325
23
Ramosetron Investigational Phase 4 132036-88-5
24
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
25 Anti-Anxiety Agents Phase 4
26 Emetics Phase 4
27 Psychotropic Drugs Phase 4
28 Antipsychotic Agents Phase 4
29 Antipyretics Phase 4
30 Vitamins Phase 4
31 Dermatologic Agents Phase 4
32 Chlorhexidine gluconate Phase 4
33 Disinfectants Phase 4
34 Respiratory System Agents Phase 4
35 Anti-Infective Agents, Local Phase 4
36 Expectorants Phase 4
37 Monoamine Oxidase Inhibitors Phase 4
38 Antimalarials Phase 4
39 Anesthetics, Local Phase 4
40 Narcotics Phase 4
41 Analgesics, Opioid Phase 4
42 Anesthetics, General Phase 4
43 Anesthetics, Intravenous Phase 4
44 Hormones Phase 4
45 Antineoplastic Agents, Hormonal Phase 4
46 Hormone Antagonists Phase 4
47 glucocorticoids Phase 4
48 Anesthetics Phase 4
49 Antiemetics Phase 4
50 Opiate Alkaloids Phase 4

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
3 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
4 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
5 Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube Unknown status NCT01501227 Phase 4
6 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
7 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
8 Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
9 Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial Completed NCT00708149 Phase 4 lansoprazole OD;placebo
10 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
11 Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Completed NCT02873065 Phase 4 Ilaprazole;Esoprazole
12 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
13 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
14 Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study. Completed NCT00590928 Phase 4 esomeprazole;ranitidine
15 An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours Completed NCT00428701 Phase 4 Esomeprazole Sodium
16 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
17 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
18 Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
19 Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial Completed NCT01180179 Phase 4 Lansoprazole;Famotidine
20 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
21 Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study. Completed NCT00594867 Phase 4 Acetaminophen - 4 grams per day + Placebo;Aspirin - 325 mg per day + Placebo;Acetaminophen 4 gram per day + Aspirin 325 mg per day
22 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
23 Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit Completed NCT00633035 Phase 4 esomeprazole 40 mg;famotidine 20 mg
24 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
25 Improving Multivitamin Supplementation to Pregnant Women Completed NCT02300155 Phase 4 Pregvit®;Orifer F®
26 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
27 The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood Completed NCT01756209 Phase 4 Magnesium 400Mg;Ibuprofen 10 mg/kg;acetaminophen 15 mg/kg
28 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
29 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
30 Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial Completed NCT00610324 Phase 4 Chlorhexidine gluconate;Potassium permanganate
31 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
32 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Recruiting NCT03667703 Phase 4 Famotidine;Placebo
33 Do We Need to Taper Down Steroid Therapy for Bell's Palsy: A Prospective Randomized Controlled Trial Recruiting NCT04406376 Phase 4 Prednisone tablet
34 Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study Recruiting NCT04028466 Phase 4 Vonoprazan;Omeprazole
35 Combined Erector Muscle Spinae Plane Block and General Anaesthesia Versus General Anaesthesia Alone - Effect on Perioperative Opioid Consumption in Open Heart Surgery Recruiting NCT04338984 Phase 4 General anesthetic;Ropivacaine 0.5% Injectable Solution
36 Effect of Adding Azithromycin to Dexamethasone in Preventing Post-operative Nausea and Vomiting in Caesarean Section Under Spinal Anesthesia With Spinal Opiate. Not yet recruiting NCT03165123 Phase 4 Oral Azithromycin tablet;Intravenous dexamethasone
37 A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery Terminated NCT00220909 Phase 4 Lansoprazole
38 Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery Terminated NCT00839488 Phase 4 pantoprazole 40 mg iv;famotidine 20 mg iv
39 Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
40 A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer Withdrawn NCT00247130 Phase 4 Omeprazole;Ranitidine
41 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
42 Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial Unknown status NCT02929563 Phase 3 Pantoprazole;Placebo (for pantoprazole)
43 Non Inferiority,Phase III,Multicentric,Double Blind,Randomized,Parallel Study,Comparing Dolamin Flex (Lysine Clonixinate+Cyclobenzaprine) and Tandrilax(Caffeine +Carisoprodol+Diclofenac+Paracetamol)in Pain Reduction in Patients With Lumbago Unknown status NCT01421433 Phase 3 Tandrilax;Dolamin Flex
44 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
45 The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin Unknown status NCT00281047 Phase 2, Phase 3 FP-10
46 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
47 Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy Unknown status NCT02449954 Phase 2, Phase 3 Intravenous morphine sulphate;Intravenous tramadol HCL;Intravenous ketorolac tromethamine
48 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
49 A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use Completed NCT01069939 Phase 3 Esomeprazole;Placebo
50 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo

Search NIH Clinical Center for Duodenal Ulcer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
lansoprazole
magaldrate
Magnesium Hydroxide
Maprotiline
Maprotiline Hydrochloride
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Prazepam
rabeprazole
Sucralfate

Cochrane evidence based reviews: duodenal ulcer

Sources

Genetic Tests for Duodenal Ulcer

About this section
Sources

Anatomical Context for Duodenal Ulcer

About this section

MalaCards organs/tissues related to Duodenal Ulcer:

40
Testes, Liver, Colon, Pancreas, Heart, Small Intestine, Lung
Sources

Publications for Duodenal Ulcer

About this section

Articles related to Duodenal Ulcer:

(show top 50) (show all 17129)
# Title Authors PMID Year
1
Associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease in Chinese Han population. 54 61
19804405 2010
2
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 54 61
19930551 2009
3
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 54 61
19710266 2009
4
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. 61 54
19318661 2009
5
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 61 54
19399945 2009
6
The prevalence of the duodenal ulcer promoting gene (dupA) in Helicobacter pylori isolates varies by ethnic group and is not universally associated with disease development: a case-control study. 54 61
19338650 2009
7
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
8
Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. 61 54
18809506 2008
9
The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. 54 61
19260336 2008
10
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 54 61
18179773 2008
11
Effects of Helicobacter pylori Infection on gastric mucin expression. 61 54
18097286 2008
12
Stress ulcer prophylaxis in hospitalized patients not in intensive care units. 61 54
17592004 2007
13
Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. 54 61
17309748 2007
14
Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. 61 54
17539287 2007
15
Association between interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric carcinogenesis in a Chinese population. 61 54
17295877 2007
16
The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. 61 54
17044024 2007
17
Analysis of serum antibody profile against H pylori VacA and CagA antigens in Turkish patients with duodenal ulcer. 54 61
17106939 2006
18
[Expression of gastrin, somatostatin, PCNA and Fas-L in the mucosa of gastric antrum of children with chronic gastritis and duodenal ulcer]. 54 61
17229384 2006
19
Detection of Helicobacter pylori cagA gene in gastric biopsies, clinical isolates and faeces. 61 54
16912439 2006
20
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 61 54
16868800 2006
21
Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. 54 61
16550552 2006
22
Assay of gastrin and somatostatin in gastric antrum tissues of children with chronic gastritis and duodenal ulcer. 54 61
16610039 2006
23
[The part of the hormone-cyclase system in achieving the therapeutic effect of hydrochloric acid secretion inhibitors at the duodenal ulcer]. 54 61
16866262 2006
24
Development of a novel method to detect Helicobacter pylori cagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. 61 54
16543737 2006
25
IL1RN polymorphism and cagA-positive Helicobacter pylori strains increase the risk of duodenal ulcer in children. 54 61
16183821 2005
26
No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. 54 61
16164697 2005
27
[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. 54 61
16174594 2005
28
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. 61 54
16110845 2005
29
Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. 54 61
15849833 2005
30
The humoral immuneresponse to Helicobacter pylori infection in children with gastrointestinal symptoms. 54 61
15866217 2005
31
Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. 54 61
15762883 2005
32
Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. 61 54
15652446 2005
33
[Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. 61 54
17378383 2005
34
Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. 54 61
16325508 2005
35
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 61 54
15627645 2004
36
TNF/LTA polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean population. 54 61
15381184 2004
37
High prevalence of multiple strain colonization of Helicobacter pylori in Korean patients: DNA diversity among clinical isolates from the gastric corpus, antrum and duodenum. 61 54
15053036 2004
38
The diversity of vacA and cagA genes of Helicobacter pylori in East Asia. 54 61
14734191 2004
39
Lewis antigen expression in gastric mucosa of children: relationship with Helicobacter pylori infection. 54 61
14676601 2004
40
Helicobacter pylori-induced immunological responses in patients with duodenal ulcer and in patients with cardiomyopathies. 54 61
15571071 2004
41
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. 61 54
14615467 2003
42
Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. 54 61
14632761 2003
43
[Effect of quamatel on neutrophil properties, parameters of lipid peroxidation and the antioxidant defense system in blood of patients with duodenal ulcer and pancreatitis]. 54 61
14743716 2003
44
History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. 61 54
14567455 2003
45
Local and peripheral cytokine response and CagA status of Helicobacter pylori-positive patients with duodenal ulcer. 54 61
14656687 2003
46
DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh. 54 61
12734242 2003
47
Helicobacter pylori genotypes and expression of gastritis in erosive gastro-oesophageal reflux disease. 61 54
12795459 2003
48
Significance of an exaggerated meal-stimulated gastrin response in pathogenesis of Helicobacter pylori-negative duodenal ulcer. 54 61
12741450 2003
49
Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B -31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. 54 61
12788304 2003
50
[Association between Helicobacter pylori virulence and duodenal ulcer disease in patients from Hong Kong in China]. 61 54
12697114 2003
Sources

Variations for Duodenal Ulcer

About this section
Sources

Expression for Duodenal Ulcer

About this section
Search GEO for disease gene expression data for Duodenal Ulcer.
Sources

Pathways for Duodenal Ulcer

About this section

Pathways related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.05 TNF S100A8 LTA INS IL6 IL1RN
2
PEDF Induced Signaling 63
Show member pathways
 13.7 TNF LTA INS IL6 IL1RN IL1B
3
TGF-Beta Pathway 63
Show member pathways
 13.56 TNF LTA INS IL6 IL1B IL10
4
Akt Signaling 63
Show member pathways
 13.42 TNF LTA IL6 IL1B IL10 EGF
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.39 TNF LTA IL6 IL1RN IL1B IL10
6
PAK Pathway 63
Show member pathways
 13.32 TNF LTA IL6 IL1B IL10 EGF
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.08 TNF IL6 IL1B IL10 EGF CXCL8
8
Allograft rejection 1 36
Show member pathways
 12.9 TNF LTA INS IL6 IL1B IL10
9
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.74 TNF IL6 IL1RN IL1B CXCL8
10
NF-KappaB Family Pathway 63
Show member pathways
 12.72 TNF LTA IL6 IL1B EGF
11
T cell receptor signaling pathway 36
Show member pathways
 12.62 TNF IL6 IL1B IL10 EGF
12
Immune response IL-23 signaling pathway 22
Show member pathways
 12.6 TNF IL6 IL1B IL10 CXCL1
13
Folate Metabolism 1
Show member pathways
 12.35 TNF INS IL6 IL1B
14
IL-17 Family Signaling Pathways 64
Show member pathways
 12.34 TNF S100A8 IL6 IL1B CXCL8 CXCL1
15
Salmonella infection (KEGG) 36
12.32 TNF IL6 IL1B CXCL8
16
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.32 TNF LTA IL6 IL10 CXCL8 CXCL1
17
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.31 TNF LTA IL6 IL1B IL10 CXCL8
18
NOD-like receptor signaling pathway 36
12.29 TNF IL6 IL1B CXCL8 CXCL1
19
Pathogenic Escherichia coli infection 36
12.28 TNF IL6 IL1B CXCL8
20
Tuberculosis 36
12.25 TNF IL6 IL1B IL10
21
C-type lectin receptor signaling pathway 36
Show member pathways
 12.23 TNF IL6 IL1B IL10
22
Bacterial infections in CF airways 22
Show member pathways
 12.21 TNF IL6 IL1B CXCL8
23
FoxO signaling pathway 36
Show member pathways
 12.1 INS IL6 IL10 EGF
24
Yersinia infection 36
12.08 TNF IL6 IL1B IL10 CXCL8
25
Spinal Cord Injury 1
12.08 TNF IL6 IL1B CXCL8 CXCL1
26
Interleukin-4 and 13 signaling 65
12.05 TNF IL6 IL1B IL10 CXCL8
27
TNF signaling pathway 36
12.03 TNF LTA IL6 IL1B CXCL1
28
Senescence and Autophagy in Cancer 1
11.99 INS IL6 IL1B CXCL8 CXCL1
29
IL27-mediated signaling events 1
Show member pathways
 11.98 TNF LTA IL6 IL1B IL10
30
AGE-RAGE signaling pathway in diabetic complications 36
11.95 TNF IL6 IL1B CXCL8
31
NF-kappa B signaling pathway 36
11.95 TNF LTA IL1B CXCL8 CXCL1
32
Rheumatoid arthritis 36
11.86 TNF IL6 IL1B CXCL8 CXCL1
33
Innate Lymphoid Cells Differentiation 64
11.85 TNF LTA IL1B IL10
34
Dendritic Cells Developmental Lineage Pathway 64
11.81 TNF IL6 IL1B IL10
35
Amoebiasis 36
11.81 TNF IL6 IL1B IL10 CXCL8 CXCL1
36
Pertussis 36
11.74 TNF IL6 IL1B IL10 CXCL8
37
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.72 TNF IL6 IL1B CXCL8
38
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.71 TNF SST IL6 IL1RN IL1B IL10
39
Lung fibrosis 1
11.63 TNF IL6 IL1B EGF CXCL8
40
ATF-2 transcription factor network 1
11.61 INS IL6 CXCL8
41
Legionellosis 36
11.56 TNF IL6 IL1B CXCL8 CXCL1
42
Hematopoietic Stem Cell Differentiation 1
11.54 IL6 IL1B ABO
43
Differentiation Pathway 1
11.54 INS IL6 EGF
44
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 TNF IL6 IL1B
45
Malaria 36
11.47 TNF IL6 IL1B IL10 CXCL8
46
African trypanosomiasis 36
11.45 TNF IL6 IL1B IL10
47
IL-10 Pathway 63
11.39 TNF IL6 IL1B IL10
48
Development and heterogeneity of the ILC family 1
11.34 TNF IL6 IL1B
49
Antifolate resistance 36
11.33 TNF IL6 IL1B
50
Cytokines and Inflammatory Response 1
11.12 TNF IL6 IL1B IL10 CXCL1
Sources

GO Terms for Duodenal Ulcer

About this section

Cellular components related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF SST SCT S100A8 LTA INS
2 extracellular region GO:0005576 9.58 TNF SST SCT S100A8 PSCA LTA

Biological processes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.08 TNF INS IL6 IL1B EGF
2 G protein-coupled receptor signaling pathway GO:0007186 10.06 SST SCT INS HRH2 GRP GAST
3 negative regulation of cell proliferation GO:0008285 10.03 SST IL6 IL1B IL10 CXCL8 CXCL1
4 cell-cell signaling GO:0007267 9.99 SST LTA INS IL1B
5 response to lipopolysaccharide GO:0032496 9.95 S100A8 LTA IL1B IL10
6 inflammatory response GO:0006954 9.91 TNF S100A8 IL6 IL1RN IL1B CXCL8
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.89 TNF IL6 IL1B IL10
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF S100A8 INS IL6 IL1B
9 humoral immune response GO:0006959 9.84 TNF LTA IL6
10 neutrophil chemotaxis GO:0030593 9.84 S100A8 IL1B CXCL8 CXCL1
11 positive regulation of interleukin-6 production GO:0032755 9.83 TNF IL6 IL1B
12 regulation of synaptic plasticity GO:0048167 9.83 SCT INS HRH2
13 positive regulation of interferon-gamma production GO:0032729 9.8 TNF LTA IL1B
14 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B IL10 CXCL8 CXCL1
15 cytokine-mediated signaling pathway GO:0019221 9.8 TNF IL6 IL1RN IL1B IL10 CXCL8
16 positive regulation of cytokine secretion GO:0050715 9.78 TNF INS IL10
17 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL1RN IL10
18 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL10
19 signal transduction GO:0007165 9.77 LTA INS IL6 IL1RN IL1B IL10
20 negative regulation of neurogenesis GO:0050768 9.76 TNF IL6 IL1B
21 positive regulation of mitotic nuclear division GO:0045840 9.75 INS IL1B EGF
22 leukocyte chemotaxis GO:0030595 9.72 IL10 CXCL8 CXCL1
23 embryonic digestive tract development GO:0048566 9.7 TNF SCT CXCL8
24 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.69 IL1RN IL10
25 response to molecule of bacterial origin GO:0002237 9.69 IL10 CXCL8
26 negative regulation of lipid catabolic process GO:0050995 9.69 TNF INS IL1B
27 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
28 positive regulation of peptide hormone secretion GO:0090277 9.68 INS GRP
29 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
30 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
31 positive regulation of lipid catabolic process GO:0050996 9.67 SCT IL1B
32 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.67 IL6 IL1RN
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 TNF IL1B IL10
34 negative regulation of cytokine production involved in immune response GO:0002719 9.65 TNF IL10
35 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.64 TNF LTA
37 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 TNF IL10
38 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 TNF IL1B
40 receptor biosynthetic process GO:0032800 9.61 TNF IL10
41 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6 IL1B
42 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.57 TNF LTA
43 positive regulation of glial cell proliferation GO:0060252 9.46 TNF LTA IL6 IL1B
44 immune response GO:0006955 9.28 TNF LTA IL6 IL1RN IL1B IL10

Molecular functions related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IL10 EGF CXCL1
2 hormone activity GO:0005179 9.35 SST SCT INS GAST CCK
3 cytokine activity GO:0005125 9.23 TNF LTA IL6 IL1RN IL1B IL10
Sources

Sources for Duodenal Ulcer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....